Protara Therapeutics annual ebitda
2012
2013
2014
2015
2016
Protara Therapeutics EBITDA Growth & History (TARA)
Protara Therapeutics's calculated EBITDA was −$28.6M for fiscal 2016.
View full Protara Therapeutics company overviewProtara Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2016 | 2016-12-31 | −$28.6M | −$7.8M | — |
| 2015 | 2015-12-31 | −$20.8M | −$13.3M | — |
| 2014 | 2014-12-31 | −$7.5M | −$455,000 | — |
| 2013 | 2013-12-31 | −$7.1M | $844,000 | — |
| 2012 | 2012-12-31 | −$7.9M | — | — |
Protara Therapeutics quarterly ebitda
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2017 | 2017-09-30 | −$12.3M | −$5.1M | — |
| Q2 2017 | 2017-06-30 | −$5.9M | $1.9M | — |
| Q1 2017 | 2017-03-31 | −$6.4M | $355,000 | — |
| Q4 2016 | 2016-12-31 | −$6.8M | −$667,000 | — |
| Q3 2016 | 2016-09-30 | −$7.1M | −$2.1M | — |
| Q2 2016 | 2016-06-30 | −$7.8M | −$2.9M | — |
| Q1 2016 | 2016-03-31 | −$6.8M | −$2.2M | — |
| Q4 2015 | 2015-12-31 | −$6.2M | −$2.9M | — |
| Q3 2015 | 2015-09-30 | −$5.1M | −$5.2M | — |
| Q2 2015 | 2015-06-30 | −$5.0M | −$2.5M | — |
| Q1 2015 | 2015-03-31 | −$4.6M | −$2.7M | — |
| Q4 2014 | 2014-12-31 | −$3.3M | — | — |
| Q3 2014 | 2014-09-30 | $142,000 | — | — |
| Q2 2014 | 2014-06-30 | −$2.5M | — | — |
| Q1 2014 | 2014-03-31 | −$1.9M | — | — |
Protara Therapeutics ebitda trends
Across the available reported history, Protara Therapeutics's ebitda decreased from −$20.8M to −$28.6M, a change of −$7.8M. The latest reported quarter, Q3 2017, shows −$12.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protara Therapeutics filings at SEC.gov ↗